UEG Week 2022

Is IL-23 the super target?

What is the best dose of adalimumab in CD?

The benefit of early intervention in CD

What is new in anti-TNFα therapy?

Personalized therapy - de-escalation strategies

Treat-to-target with ustekinumab - why didn't it work?

Treat-to-target still alive?

Longterm potential benefit of a combIo therapy

Treat-to-target strategy is superior to conventional step-care in active patients to gain remission

Thinking out of the box - co-medication of the elderly

Pharmacokinetics of ustekinumab in the STARDUST trial

Combination therapy: week 38 efficacy and safety data from the VEGA study

Anti-IL-23 monoclonal antibodies: is it better to target IL-23 only than IL-23 and IL-12?

T reg - a new therapeutic target in IBD?

Small molecules in crohn's disease

Enhanced treatment algorithm for the management of CD

No matter what you use - treat early!

VEGA - the story continues

Postoperative monitoring matters!

TYK2 Deucravacitinib in ulcerative colitis

You can still treat severe biofailure in CD

Once more a shocking message: be aware of steroids!

Oral anti-integrin therapy in IBD - new data, new chances?

Explosion of new drugs

Treating the patient as a whole

Les résultats à long terme d'une combIothérapie

T reg - nowy cel terapeutyczny w IBD?

TYK2 Deucravacitinib bei Colitis ulcerosa

Anticorps anti-IL-23: est-il préferabble de cibler l'IL-23 seule plutôt que l'IL-12 et l'IL-23?

Terapia di combinazione: efficacia e sicurezza a 38 settimane nello studio VEGA

Thinking out of the box - Einfluss der Begleitmedikation bei älteren Patienten

Treating the patient as a whole

Explosión de nuevos fármacos

Una strategia “Treat-to-target” è superiore rispetto and un approccio convenzionale nel raggiungimento della remissione in pazienti con malattia attiva

Doustna terapia antyintegrynowa - nowe dane, nowe nadzieje?

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

VEGA - l'histoire continue

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα κορτικοστεροιδή!

Small molecules nel morbo di crohn

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά νόσο του Crohn

Was tun nach der Operation?

S1P receptor modulators

Update on IL-23 inhibition in UC

1st JAK inhibitor in CD - a game changer?

Update on JAK inhibition in UC

Risankizumab in refractory CD patients

Persistance on therapy and real-world clinical effectiveness of Tofacitinib in ulcerative colitis: data from the ENEIDA registry

Estrasimod in moderate to severe active UC

Final efficacy and safety results from Upadacitinib 52 weeks maintenance trial in UC patients

Upadacitinib - induction therapy in CD

Upadacitinib maintenance therapy - final results from U-ACHIEVE

Selective IL-23 blockade

Ozanimod works in young and old UC patient

The 1st JAKi in CD

VEGA & LUCENT studies

Histological response and remission induced by mirikizumab

The era of small molecules

JAK-inhibition

JAK-Inhibition

The area of small molecules

Risultati finali di efficacia e sicurezza a 52 settimane di Upadacitinib in colite ulcerosa

Risankizumab dans la maladie de Crohn réfractaire

Upadacitinib - Induktionsdaten bei CD

VEGA & LUCENT studi clinici

Selective IL-23 Blockade

Persistenza in terapia ed efficaci clinica di Tofacitinib in colite ulcerosa: dati dal registro ENEIDA

Treating the elderly - closer surveillance and the importance of co-medication

Updated safety data on JAK inhibitors

Urgency - putting the focus on an important endpoint!

Steroid effects as treatment goals: quality of life and steroid free remission

Filgotinib is efficacious in inducing and maintaining histological remission in UC

Patient reported outcomes in IBD

Urgency matters!

New endpoints in IBD

Neue Studienendpunkte in IBD

Patienten gerichtete Endpunkte bei CED

Whats's the origin of Crohn's genetics ? The history of IL-23 receptor genetics in Europe

Explosion of Spanish contributions

Wo kommt die Crohn-Genetik her? Die Historie der IL-23 Rezeptorgenetik in Europa

Explosión de las comunicaciones españolas

Personalised therapy in IBD

Individualisierte Therapie bei CED